A recent study conducted on cynomolgus monkeys has shown that metformin, a medication used to treat type 2 diabetes, can slow the aging process in multiple organs, including the brain. Over a three-and-a-half-year period, the monkeys treated with metformin displayed reduced age-related decline, with some even exhibiting a six-year regression in certain aging indicators. While these findings suggest promising anti-aging benefits, further research, including human trials, is needed to explore the full potential of the drug.
Metformin has gained attention for its potential anti-aging effects due to its ability to improve insulin sensitivity, reduce inflammation, and promote cellular repair processes—all of which are important factors in aging. In a new study conducted by experts in China and the US, it was discovered that administering metformin to cynomolgus monkeys slowed the aging process across various organs, including the brain. The researchers conducted a nearly three-and-a-half-year study on the effects of metformin on the monkeys’ bodies and found evidence of slowed biological aging in organs like the kidneys, lungs, and skin.
The team collected tissue samples from multiple organs, conducted brain imaging, and performed physical and cognitive tests throughout the study to assess changes in biological age at the cellular level. They found that biological aging slowed down in several organs by up to 5.1 years. The researchers also observed a significant impact on brain aging, with all monkeys experiencing a reduction in age-related decline. Metformin preserved brain structure and improved cognitive function, likely due to its activation of Nrf2, a protein known for its anti-oxidative properties.
While the study provides valuable insights into metformin’s geroprotective mechanism, the researchers acknowledge its limitations, including the focus on a single gender and the lack of human trials to confirm the findings. However, the findings offer promising new avenues for understanding how aging can potentially be slowed down and disease risk reduced. With more research, metformin could play a role in managing age-related diseases more effectively and promoting overall longevity.
Anecdotally, healthcare professionals have observed that patients on metformin often report fewer dental issues and healthier gums, aligning with the idea that reducing inflammation and slowing cellular aging could benefit oral health. It is crucial to conduct more clinical trials and long-term studies to determine if metformin’s effects on aging observed in monkeys also translate to humans. If successful, metformin could delay the onset of age-related diseases, improve organ function, and promote overall longevity when integrated with healthy lifestyle choices.
